Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

High-Dose Vincristine Sulfate Liposome Injection (Marqibo ® ) Is Not Associated With Clinically Meaningful Hematologic Toxicity

Olivia R. Deitcher, John Glaspy, MD, Rene Gonzalez, MD, Takami Sato, Agop Bedikian, MD, Karen Segarini, Jeffrey A. Silverman, Ph.D., Steven R. Deitcher, MD

Blood (2013) 122 (21): 2676.

https://doi.org/10.1182/blood.V122.21.2676.2676

Published: 2013

Journal Articles

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Steven R. Deitcher, MD, Anas Younes, MD, Luis Fayad, MD, Andre Goy, MD, Nam H. Dang, MD, PhD, A Forman, MD, Peter McLaughlin, MD, Barbara Pro, MD, Jorge Enrique Romaguera, Felipe Samaniego, MD, Jeffrey A. Silverman, Ph.D., Andreas H. Sarris, MD, PhD, Fernando Cabanillas, MD

Blood (2013) 122 (21): 3033.

https://doi.org/10.1182/blood.V122.21.3033.3033

Published: 2013

Journal Articles

Vincristine Sulfate Liposome Injection (Marqibo ® ) and Rituximab For Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma Or Mantle Cell Lymphoma In Need Of Palliative Therapy

Lawrence D. Kaplan, MD, Steven R. Deitcher, MD, Jeffrey A. Silverman, Ph.D., Gareth J Morgan, MD, PhD

Blood (2013) 122 (21): 4355.

https://doi.org/10.1182/blood.V122.21.4355.4355

Published: 2013

Journal Articles

Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) Facilitates Increased Delivery of Vincristine Sulfate to Target Cancer Tissues.

Jeffrey A. Silverman, Ph.D., Steven R. Deitcher, MD

Blood (2012) 120 (21): 2457.

https://doi.org/10.1182/blood.V120.21.2457.2457

Published: 2012

Journal Articles

Neurotoxicity Profile of Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) Monotherapy in Adults with Relapsed Acute Lymphoblastic Leukemia and Universal Prior Standard Vincristine Exposure

Steven R. Deitcher, MD, Jeffrey A. Silverman, Ph.D.

Blood (2012) 120 (21): 3568.

https://doi.org/10.1182/blood.V120.21.3568.3568

Published: 2012

Journal Articles

Minimal Residual Disease in Adults with Advanced Relapsed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Treated with Marqibo ® (vinCRIStine sulfate LIPOSOME injection)

Olivia R. Deitcher, Stuart L. Goldberg, MD, Wendy Stock, MD, Gary J. Schiller, MD, John Lister, MD, Jeffrey A. Silverman, Ph.D., Steven R. Deitcher, MD, Susan O'Brien, M.D.

Blood (2012) 120 (21): 4805.

https://doi.org/10.1182/blood.V120.21.4805.4805

Published: 2012

Journal Articles

Design of the Hallmarq Trial, a Phase 3 Study of Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) in Adults with Newly Diagnosed, Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia

Steven R. Deitcher, MD, Jeffrey A. Silverman, Ph.D.

Blood (2012) 120 (21): 4300.

https://doi.org/10.1182/blood.V120.21.4300.4300

Published: 2012

Journal Articles

Single-Agent Vincristine Sulfate Liposomes Injection (Marqibo ® ) Compared to Historical Single-Agent Therapy for Adults with Advanced, Relapsed and/or Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia

Olivia R. Deitcher, Susan O'Brien, MD, Steven R. Deitcher, MD, Deborah A. Thomas, Hagop M. Kantarjian

Blood (2011) 118 (21): 2592.

https://doi.org/10.1182/blood.V118.21.2592.2592

Published: 2011

Journal Articles

Neurological Toxicity Profile of Weekly Vincristine Sulfate Liposomes Injection (Marqibo ® ) 2.25 mg/m 2 Compared to Historical Standard Vincristine Sulfate 1.4 mg/m 2 , 2 mg, and 4 mg Administered Less Frequently

Lloyd E. Damon, MD, Stuart L. Goldberg, MD, Leonard T. Heffner, MD, John Lister, MD, Gary J. Schiller, MD, Steven R. Deitcher, MD

Blood (2011) 118 (21): 4247.

https://doi.org/10.1182/blood.V118.21.4247.4247

Published: 2011

Journal Articles

Vincristine Sulfate Liposomes Injection (Marqibo ® ) Facilitates Durable Remissions and Potentially Curative Hematopoietic Stem Cell Transplantation in Adults with Advanced, Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Gary J. Schiller, MD, John Lister, MD, Leonard T. Heffner, MD, Stuart L. Goldberg, MD, Lloyd E. Damon, MD, Jeffrey A. Silverman, Ph.D., Steven R. Deitcher, MD

Blood (2011) 118 (21): 4235.

https://doi.org/10.1182/blood.V118.21.4235.4235

Published: 2011

Journal Articles

Marqibo ® (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) In Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL)

Jeffrey A Silverman, PhD, Walter E. Aulitzky, MD, John Lister, MD, Lori Maness, M.D., Gary J Schiller, MD, Karen Seiter, MD, Scott Smith, MD, PhD, FACP, Wendy Stock, MD, Dina Ben Yehuda, Steven R. Deitcher, MD

Blood (2010) 116 (21): 2142.

https://doi.org/10.1182/blood.V116.21.2142.2142

Published: 2010

Journal Articles

Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines.

Susan O'Brien, MD, Gary Schiller, Lloyd E. Damon, MD, John Lister, MD, Farhad Ravandi, MD, Dan Douer, MD, Aisha Masood, MD, Dina Ben-Yehuda, Jacob M. Rowe, MD, Nicola Gökbuget, Walter Aulitzky, Wendy Stock, MD, Steven Coutre, MD, Leonard Heffner, MD, Melissa L. Larson, MD, Karen Seiter, MD, Anne E Hagey, MD, Steven R. Deitcher, MD, Hagop M. Kantarjian, MD

Blood (2009) 114 (22): 3088.

https://doi.org/10.1182/blood.V114.22.3088.3088

Published: 2009

Journal Articles

In Vivo Anti-Tumor Efficacy of Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Multiple Myeloma

Eric Sanchez, Jeffrey A Steinberg, Mingjie Li, Haiming Chen, MD, PhD, Benjamin Bonavida, PhD, Steven R. Deitcher, MD, Anne E Hagey, MD, James R. Berenson, MD

Blood (2008) 112 (11): 2760.

https://doi.org/10.1182/blood.V112.11.2760.2760

Published: 2008

Journal Articles

Peripheral Neuropathy Profile of Vincristine Sulfate Liposomes Injection (VSLI, Marqibo ® ), a Nanoparticle Vincristine Formulation, in Adult Subjects with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin’s Lymphoma (NHL)

Biao Lu, PhD, Anne E Hagey, MD, Feng Zhou, MS, Steven R. Deitcher, MD

Blood (2008) 112 (11): 2928.

https://doi.org/10.1182/blood.V112.11.2928.2928

Published: 2008

Journal Articles

Phase 1 Study of Weekly Vincristine Sulfate (VCR) Liposomes Injection (VSLI, Marqibo ™ ) Plus Dexamethasone in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Deborah A. Thomas, MD, Hagop M Kantarjian, MD, Wendy Stock, MD, Leonard Heffner, MD, Sue Hirabayashi, MBA, Biao Lu, PhD, Steven R. Deitcher, MD, Susan O’Brien, MD

Blood (2008) 112 (11): 2930.

https://doi.org/10.1182/blood.V112.11.2930.2930

Published: 2008

Journal Articles

Safety and Efficacy of Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) in for the Treatment of Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Wendy Stock, MD, Leonard Heffner, MD, Alexandra Tredinnick, Baio Lu, Gavin S. Choy, Steven R. Deitcher, MD, Susan M. O’Brien, MD

Blood (2007) 110 (11): 858.

https://doi.org/10.1182/blood.V110.11.858.858

Published: 2007

Journal Articles

Marqibo (Vincristine Sulfate Liposomes Injection (OPTISOME™) Demonstrates Activity in Patients with Relapsed and Refractory Peripheral T-Cell Lymphoma.

M. Alma Rodriguez, MD, Jane N. Winter, MD, Biao Lu, PhD, Gary Huang, MD, Gavin S. Choy, PharmD, Steven R. Deitcher, MD

Blood (2007) 110 (11): 4466.

https://doi.org/10.1182/blood.V110.11.4466.4466

Published: 2007

Journal Articles

rNAPc2, a Novel Inhibitor of Tissue Factor/Factor VIIa Complex, Suppresses Lung Metastasis and Synergizes with 5-FU or Bevacizumab in Mouse Models of Colorectal Cancer.

Jingsong Zhao, PhD, Gerard Aguilar, Steven R. Deitcher, MD, Walter Funk, PhD, Arie Abo, PhD

Blood (2006) 108 (11): 904.

https://doi.org/10.1182/blood.V108.11.904.904

Published: 2006

Journal Articles

Thromboelastographic (TEG) Characterization of Patients with Hematologic Malignancy and Chemotherapy Induced Thrombocytopenia (CIT).

Jatin J. Shah, MD, Marcelo P.V. Gomes, MD, Steven R. Deitcher, MD

Blood (2004) 104 (11): 2729.

https://doi.org/10.1182/blood.V104.11.2729.2729

Published: 2004

Journal Articles

Safety and Efficacy of Alfimeprase for Restoring Function in Occluded Central Venous Catheters: Interim Results of a Phase 2, Multicenter, Randomized, Double-Blind Study (NuCath).

Steven R. Deitcher, MD, Stephan Moll, MD, Howard D. Homesley, MD, Luigi Bertoli, MD, Peter Kenyon, MD, Peter Swischuk, MD, Luis Pena

Blood (2004) 104 (11): 1768.

https://doi.org/10.1182/blood.V104.11.1768.1768

Published: 2004

NARROW

High-Dose Vincristine Sulfate Liposome Injection (Marqibo ® ) Is Not Associated With Clinically Meaningful Hematologic Toxicity

Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo ® ) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas

Vincristine Sulfate Liposome Injection (Marqibo ® ) and Rituximab For Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma Or Mantle Cell Lymphoma In Need Of Palliative Therapy

Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) Facilitates Increased Delivery of Vincristine Sulfate to Target Cancer Tissues.

Neurotoxicity Profile of Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) Monotherapy in Adults with Relapsed Acute Lymphoblastic Leukemia and Universal Prior Standard Vincristine Exposure

Minimal Residual Disease in Adults with Advanced Relapsed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Treated with Marqibo ® (vinCRIStine sulfate LIPOSOME injection)

Design of the Hallmarq Trial, a Phase 3 Study of Vincristine Sulfate Liposome Injection (VSLI, Marqibo®) in Adults with Newly Diagnosed, Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia

Single-Agent Vincristine Sulfate Liposomes Injection (Marqibo ® ) Compared to Historical Single-Agent Therapy for Adults with Advanced, Relapsed and/or Refractory Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia

Neurological Toxicity Profile of Weekly Vincristine Sulfate Liposomes Injection (Marqibo ® ) 2.25 mg/m 2 Compared to Historical Standard Vincristine Sulfate 1.4 mg/m 2 , 2 mg, and 4 mg Administered Less Frequently

Vincristine Sulfate Liposomes Injection (Marqibo ® ) Facilitates Durable Remissions and Potentially Curative Hematopoietic Stem Cell Transplantation in Adults with Advanced, Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Marqibo ® (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) In Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL)

Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines.

In Vivo Anti-Tumor Efficacy of Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Multiple Myeloma

Peripheral Neuropathy Profile of Vincristine Sulfate Liposomes Injection (VSLI, Marqibo ® ), a Nanoparticle Vincristine Formulation, in Adult Subjects with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin’s Lymphoma (NHL)

Phase 1 Study of Weekly Vincristine Sulfate (VCR) Liposomes Injection (VSLI, Marqibo ™ ) Plus Dexamethasone in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Safety and Efficacy of Marqibo (Vincristine Sulfate Liposomes Injection, OPTISOME™) in for the Treatment of Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL).

Marqibo (Vincristine Sulfate Liposomes Injection (OPTISOME™) Demonstrates Activity in Patients with Relapsed and Refractory Peripheral T-Cell Lymphoma.

rNAPc2, a Novel Inhibitor of Tissue Factor/Factor VIIa Complex, Suppresses Lung Metastasis and Synergizes with 5-FU or Bevacizumab in Mouse Models of Colorectal Cancer.

Thromboelastographic (TEG) Characterization of Patients with Hematologic Malignancy and Chemotherapy Induced Thrombocytopenia (CIT).

Safety and Efficacy of Alfimeprase for Restoring Function in Occluded Central Venous Catheters: Interim Results of a Phase 2, Multicenter, Randomized, Double-Blind Study (NuCath).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only